Analysis of cardiovascular thromboembolic events with etoricoxib
Download
1 / 31

Analysis of Cardiovascular Thromboembolic Events With Etoricoxib - PowerPoint PPT Presentation


  • 188 Views
  • Uploaded on

Analysis of Cardiovascular Thromboembolic Events With Etoricoxib. Joel Schiffenbauer, M.D. DAAODP, ODE V February 17, 2005. Etoricoxib. NDA indications include: OA, CLBP, RA, AS, acute gout, acute pain, dysmenorrhea Proposed doses: 60 and 90 mg chronically and 120 mg acutely

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Analysis of Cardiovascular Thromboembolic Events With Etoricoxib' - holleb


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Analysis of cardiovascular thromboembolic events with etoricoxib

Analysis of Cardiovascular Thromboembolic Events With Etoricoxib

Joel Schiffenbauer, M.D.

DAAODP, ODE V

February 17, 2005


Etoricoxib
Etoricoxib Etoricoxib

  • NDA indications include: OA, CLBP, RA, AS, acute gout, acute pain, dysmenorrhea

    • Proposed doses: 60 and 90 mg chronically and 120 mg acutely

  • EDGE study: Etoricoxib vs. Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness


Etoricoxib1
Etoricoxib Etoricoxib

  • Exposure

  • Mortality data

  • CV/TE data

    • NDA

    • EDGE


Etoricoxib2

Etoricoxib Etoricoxib

Exposure



Edge study
EDGE Study Etoricoxib


Etoricoxib3

Etoricoxib Etoricoxib

Mortality Data


Nda deaths rates are per 100 pyr
NDA/Deaths Etoricoxib(rates are per 100 PYR)


Edge deaths
EDGE/Deaths Etoricoxib


Etoricoxib4

Etoricoxib Etoricoxib

CV/TE Events in NDA


Serious adverse events included in thrombotic cv saes
Serious Adverse Events Included in Thrombotic CV SAEs Etoricoxib

  • Cardiac

    • Acute MI

    • Fatal MI

    • Unstable angina

    • Sudden death

  • Peripheral

    • Pulmonary embolism

    • Fatal PE

    • Peripheral arterial or venous thrombosis

  • Cerebrovascular

    • Ischemic cerebrovascular stroke

    • Fatal stroke

    • TIA




Nda placebo
NDA/Placebo Etoricoxib





Nda km
NDA/KM Etoricoxib



Nda naproxen
NDA/Naproxen Etoricoxib


Nda km1
NDA/KM Etoricoxib


Etoricoxib5

Etoricoxib Etoricoxib

CV Events in EDGE Study


EDGE Etoricoxib

  • 7000 patient GI tolerability study; collect CV data; non-inferiority to diclofenac (upper limit of 95% CI for hazard ratio is 1.3)

  • Issues:

    • Non-inferiority trial (no placebo)

    • diclofenac only comparator

    • only OA, no RA

    • ASA use (30%)

    • previous Cox-2 use allowed (15% rofecoxib;

      13% celecoxib; 5% valdecoxib)

    • 2600 with >2 CV risk factors


Edge km estimates
EDGE/KM Estimates Etoricoxib





Edge hypertension
EDGE/Hypertension Etoricoxib


Edge hypertension1
EDGE/Hypertension Etoricoxib


Edge chf
EDGE/CHF Etoricoxib


Summary
Summary Etoricoxib

  • In NDA, etoricoxib trends worse in terms of CV/TE particularly cardiac/MI

  • Comparisons of etoricoxib to naproxen for CV/TE events are similar to rofecoxib/naproxen comparisons

  • Trial design concerns in EDGE (2 ongoing trials of similar design)

  • Trends in EDGE for cardiac events worse for etoricoxib, mainly in non-ASA users


ad